TITLE

FDA approves stem cell clinical trial

AUTHOR(S)
Collier, Roger
PUB. DATE
September 2010
SOURCE
CMAJ: Canadian Medical Association Journal;9/7/2010, Vol. 182 Issue 12, pE584
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the U.S. Food and Drug Administration (FDA) have authorized the biopharmaceutical company Geron Corp. to conduct the first U.S. clinical trials on human embryonic stem cells.
ACCESSION #
54111087

 

Related Articles

  • Geron Soars as First ESC Trial Clears FDA Hurdle.  // Bioworld Week;2/2/2009, Vol. 17 Issue 5, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the Phase 1 clinical trial of Geron Corp.'s GRNOPCI human embryonic stem cells. Accordingly, Geron president and chief executive officer Thomas Okarma stressed that the approval has surprised everyone which pave...

  • Landmark stem cell trial delayed.  // New Scientist;8/29/2009, Vol. 203 Issue 2723, p6 

    The article deals with the decision of the U.S. Food and Drug Administration to suspend the first clinical test of human embryonic stem cells. Such cells will be transplanted into the spinal cords of paralysed patients. The cells are called oligodendrocyte progenitors which will secrete myelin...

  • Stem cell companies report some progress, much hype.  // Medical Technology & Devices Week;6/8/2009, Vol. 7 Issue 23, p2 

    The article reports on the progress made by stem cell companies after U.S. President Barack Obama lifted the ban on stem cell research. The U.S. Food and Drug Administration (FDA) has permitted Geron Corp. to start the first clinical trial based on embryonic stem cell. The issue has also been...

  • Geron gets green light for human trial of ES cell—derived product. Alper, Joe // Nature Biotechnology;Mar2009, Vol. 27 Issue 3, p213 

    The article states that the U.S. Food and Drug Administration (FDA) has approved the first human trials of embryonic stem (hES) cells. This decision came on the eve of President Barack Obama's anticipated policy change concerning such research, and it will allow the pharmaceutical company Geron...

  • Letters and Comments. Kvedar, Joseph C.; Raiu, Costin; Flygare, Julie; Hellman, Martin; Davis, J. Foster; Mehrabian, Albert // Technology Review;Sep/Oct2011, Vol. 114 Issue 5, p8 

    Several letters to the editor are presented in response to articles in the July/August, 2011 issue including "The Measured Life," by Emily Singer, "The Perfect Scam" by David Talbot, and "Stem-Cell Gamble."

  • ESC research cannot be ignored. Singh, Nandita // BioSpectrum;Jan2012, Vol. 10 Issue 1, p100 

    The author comments on the issues concerning embryonic stem cell (ESC) research in India. She highlights the decision of California-based Geron Corp. to exit in the market for ESC research to focus on other projects. She emphasizes the role of the government to impose policies to provide a clear...

  • Time to lift embryo research ban.  // Nature;11/12/1998, Vol. 396 Issue 6707, p97 

    Calls for a change in United States law regarding embryo research. Society's ability to regulate science; Advances in the culture of human embryonic stem cells; US ban on embryo research using federal funds; Lack of regulation for private sector; Geron, the company involved in embryo stem cell...

  • "CIRM Awards $25 Mln To Support Spinal-Cord Injury Trial, $37.7 Mln for Basic Stem-Cell Science".  // Biomedical Market Newsletter;5/9/2011, p143 

    The article reports that the Governing Board of the California Institute for Regenerative Medicine (CIRM), the State Stem Cell Agency, has approved a grant worth 25 million dollars to support the first U.S. Food & Drug Administration (FDA)-approved clinical trial based on cells derived from...

  • Stem cell revival. Coghlan, Andy // New Scientist;10/27/2012, Vol. 216 Issue 2888, p4 

    The article reports on attempts to resume a human embryonic stem cells (hESCs) clinical trial program cancelled in 2011 by the biotechnology company Geron, noting that former Geron officials and the biotechnology firm BioTime have placed a bid for the stem cell assets of the original program.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics